Nothing Special   »   [go: up one dir, main page]

Füchsl et al., 2022 - Google Patents

Paving the way to solid tumors: Challenges and strategies for adoptively transferred transgenic T cells in the tumor microenvironment

Füchsl et al., 2022

View HTML
Document ID
18360667156532058267
Author
Füchsl F
Krackhardt A
Publication year
Publication venue
Cancers

External Links

Snippet

Simple Summary Adoptive transfer of T cells targeting tumors still remains mainly ineffective in solid entities. In this review we discuss challenges related to the tumor microenvironment (TME) and promising strategies to improve tumor control by engineering the TME or the …
Continue reading at www.mdpi.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily

Similar Documents

Publication Publication Date Title
Christofi et al. Current perspectives in cancer immunotherapy
Hosseinkhani et al. Immune checkpoints and CAR-T cells: the pioneers in future cancer therapies?
Sobhani et al. CTLA-4 in regulatory T cells for cancer immunotherapy
Galluzzi et al. The hallmarks of successful anticancer immunotherapy
Barbari et al. Immunotherapies and combination strategies for immuno-oncology
Alard et al. Advances in anti-cancer immunotherapy: Car-T cell, checkpoint inhibitors, dendritic cell vaccines, and oncolytic viruses, and emerging cellular and molecular targets
Rath et al. Engineering strategies to enhance TCR-based adoptive T cell therapy
Dolcetti et al. Immunotherapy for gastric cancer: time for a personalized approach?
Menon et al. Advances in cancer immunotherapy in solid tumors
Seliger et al. Immune therapy resistance and immune escape of tumors
Macpherson et al. Epithelial ovarian cancer and the immune system: biology, interactions, challenges and potential advances for immunotherapy
Armengol et al. Immune-checkpoint inhibitors in B-cell lymphoma
McCloskey et al. Ovarian cancer immunotherapy: preclinical models and emerging therapeutics
Kim et al. Combining cancer vaccines with immunotherapy: establishing a new immunological approach
Gaissmaier et al. Breaking bottlenecks for the TCR therapy of cancer
Haibe et al. Resisting resistance to immune checkpoint therapy: a systematic review
Cheever et al. Tumor microenvironment immunosuppression: a roadblock to CAR T-cell advancement in solid tumors
Chen et al. Mechanisms and strategies to overcome PD-1/PD-L1 blockade resistance in triple-negative breast cancer
Zheng et al. T cells in colorectal cancer: unravelling the function of different T cell subsets in the tumor microenvironment
Tay et al. Hyper-progressive disease: the potential role and consequences of T-regulatory cells foiling anti-PD-1 cancer immunotherapy
Füchsl et al. Paving the way to solid tumors: Challenges and strategies for adoptively transferred transgenic T cells in the tumor microenvironment
Reis-Sobreiro et al. Bringing macrophages to the frontline against cancer: Current immunotherapies targeting macrophages
De Bousser et al. T cell engaging immunotherapies, highlighting chimeric antigen receptor (CAR) T cell therapy
Chung et al. Emerging approaches for solid tumor treatment using CAR-T cell therapy
Benoit et al. Lighting up the fire in the microenvironment of cold tumors: A major challenge to improve cancer immunotherapy